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1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: There are reports of an increase in vancomycin minimum
inhibitory concentration (MIC) against methicillin-resistant Staphylococcus aureus (MRSA) over
time, a phenomenon referred to as “MIC creep”, but some studies have conflicting results. The
aim of this study is to evaluate the association of molecular typing, vancomycin MIC, and clin-
ical outcome for patients with MRSA infections.
Methods: Thirty-twoMRSA isolates fromTaichungVeteransGeneral Hospital (TCVGH), Taichung,
Taiwan during the period of 2003 to 2008 were analyzed for the association of sequence typing,
vancomycin MIC, and the correlated clinical outcome for patients with MRSA infections. The van-
comycin MICs of 28 additional isolates from 2014 were used for the detection of MIC creep.
Results: Among the genotypes of 32 isolates, there were 17 (53.1%) isolates with ST239-
SCCmecIII, seven (21.9%) isolates with ST5-SCCmecII, six (18.8%) isolates with ST59-SCCmecIV,
and two (6.2%) isolates with ST59-SCCmecVT. Two isolates had an MIC of 2 mg/mL and were iden-
tified as ST239-SCCmecIII. No statistically significant change in the distribution of MICs of allfectious Diseases, Taichung Veterans General Hospital, Number 1650, Section 4, Taiwan Boulevard,
(Z.-Y. Shi).
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dx.doi.org/10.1016/j.jmii.2015.08.01isolates was observed between 2003 and 2014 (pZ 0.263). Therewas no significant difference in
themortality rates between two groups of patients with vancomycin MICs< 2 mg/mL and 2 mg/
mL (pZ > 0.99).
Conclusion: There was no vancomycin MIC creep in the period from 2003 to 2014 in this study.
Appropriate prognostic models for assessment of the association among sequence types, vanco-
mycin MICs, and clinical outcome warrant further investigation.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is highly
prevalent in hospitals worldwide, with the highest rates (>
50%) reported in North America, South America, and Asia.1
The rate of MRSA is about 60% in Taiwan, according to the
data of the Taiwan Surveillance of Antimicrobial Resis-
tance.2 Clonal complex 5 (CC5) and CC8 are the most
prevalent health care-associated MRSA (HA-MRSA) CCs
worldwide.1,3e5 CC8-ST239-SCCmecIII (63.0%), CC8-ST241-
SCCmecIII (7.6%), CC5-ST59-SCCmecIV/VT (17.2%), and
CC5-ST5-SCCmecII (5.7%), are the most common sequence
types in Taiwan.6e8
The mortality rate associated with invasive MRSA in-
fections is estimated at 20%.9 The risk factors of mortality
of S. aureus bacteremia include age and comorbidities. The
presence of shock and the source of S. aureus bacteremia
are strong predictors of outcome.10 Progressive increases in
vancomycin minimum inhibitory concentrations (MICs)
within a susceptible range (MIC creep) have been reported
in several studies.11,12 Treatment success is higher for MRSA
bacteremia with vancomycin MIC  0.5 mg/mL (55.6%) than
those with vancomycin MICs of 1e2 mg/mL (9.5%).13 Some
studies have shown that the increase in vancomycin MIC is
associated with a substantial risk of vancomycin treatment
failure for MRSA infections and a higher mortality rate,14e16
but others have suggested no significant association be-
tween higher MICs and poor outcomes.17,18
To assess the above predictors of the clinical outcome of
patients with MRSA infections, molecular typing, trend of
vancomycin MIC, and the available clinical data were
analyzed.Methods
Bacterial strains
Thirty-two non-duplicate MRSA isolates were collected
randomly from Taichung Veterans General Hospital
(TCVGH), Taichung, Taiwan during the period from October
2003 to December 2008. About six isolates each year were
randomly selected for the study. The isolates were
collected from multiple sources, including blood (37.4%),
bone (31.2%), sputum (12.5%), and skin and soft tissue
(6.2%), etc. Furthermore, 28 isolates which were randomly
collected from TCVGH during 2014 were used to detect
vancomycin MIC creep.Chen C-P, et al., The association
aphylococcus aureus infections, J
5Susceptibility test
These 32 strains were tested for susceptibility using the
Phoenix automated microbiology system (BD Diagnostic
Systems, Sparks, MD, USA). The panel of the Phoenix
automated microbiology system contained nitrofurantoin,
oxacillin, penicillin G, quinupristin-dalfopristin, rifampicin,
streptomycin, teicoplanin, tetracycline, trimethoprim-
sulfamethoxazole (TMP/SMX), and vancomycin for MIC
analysis. The MIC breakpoints were interpreted according
to the guidelines established by the Clinical and Laboratory
Standards Institute (CLSI) 2015.19
Polymerase chain reaction techniques
Multiplex polymerase chain reaction (PCR) analysis was
performed as described previously20 to distinguish the four
genetic elements for SCCmec. SCCmec typing for type VT
was determined by using a particular primer described
previously.21 The presence of Panton-Valentine leukocidin
(PVL) genes was determined by a PCR strategy described
previously.22
Multi-locus sequence typing
Multi-locus sequence typing (MLST) is well established as a
valuable method for genotyping bacteria based on the
sequence variation of housekeeping genes.23 MLST tech-
niques applied to diverse species of bacteria generally use
at least seven loci. The DNA sequences of seven house-
keeping genes were performed as described previously:
carbamate kinase (arcC ), shikimate dehydrogenase
(aroE ), glycerol kinase (glp), guanylate kinase (gmk),
phosphate acetyltransferase (pta), triosephosphate isom-
erase (tpi), and acetyl coenzyme A acetyltransferase
(yqiL). The sequence types (ST) were determined by
comparing the sequences of each gene to those of the
known alleles deposited in the S. aureus MLST database
(http://saureus.mlst.net/).
Clinical and bacteriological assessments
The clinical characteristics and outcome were reviewed
according to medical records. Community-associated MRSA
(CA-MRSA) was defined as any MRSA infection diagnosed in
an outpatient or within 48 hours of admission to hospital, of
which the patient has none of the following risk factors forof molecular typing, vancomycin MIC, and clinical outcome for
ournal of Microbiology, Immunology and Infection (2015), http://
Table 1 Clinical characteristics and outcome for patients
with methicillin-resistant Staphylococcus aureus (MRSA)
infections.
No. of patient (%)
Age (y), mean 56.1  27.1
Sex
Female 7 (21.9)
Male 25 (78.1)
Underlying diseases
Diabetes mellitus 6 (18.8)
Renal insufficiency 1 (3.1)
Cardiovascular diseases 7 (21.9)
Gastrointestinal diseases 4 (12.5)
Malignancies 4 (12.5)
Neutropenia 1 (3.1)
Respiratory diseases 3 (9.3)
Hepatobiliary diseases 4 (12.5)
Autoimmune diseases 2 (6.2)
Previous hospitalization 20 (62.5)
Previous antibiotic use 23 (71.9)
Source of infection
Primary blood stream infection 4 (12.5)
Osteomyelitis 10 (31.2)
Respiratory tract infection 4 (12.5)
Skin and soft tissue infection 10 (31.2)
Surgical site infection 2 (6.2)
Others 2 (6.2)
30 d all-cause mortality 2 (6.2)
MRSA-related 30 d mortality 2 (6.2)
Vancomycin MIC and clinical outcome of MRSA 3
+ MODELHA-MRSA: hemodialysis, surgery, residence in a long-term
care facility or treatment in hospital, presence of a per-
manent catheter or percutaneous device at the time of
culture, or previous isolation of MRSA within the previous 12
months.24 All other MRSA infections were considered to be
HA-MRSA.25
Sepsis-induced hypotension is defined as a systolic blood
pressure < 90 mmHg or mean arterial pressure < 70 mmHg,
or a systolic blood pressure decrease > 40 mmHg. Septic
shock is defined as sepsis-induced hypotension persisting
despite adequate fluid resuscitation.26
Clinical conditions (such as age, sex, underlying diseases,
source of infection, length of stay, clinical response, and
death) associated with the MRSA infection were reviewed.
The efficacy was assessed by the clinical and bacteriological
response. The clinical response was evaluated at the end of
antimicrobial treatment and defined as cure (disappearance
of acute signs and symptoms related to the infection or suf-
ficient improvement such that additional or alternative
antimicrobial treatment was not required), failure (insuffi-
cient improvement of the signs and symptoms of infection
and additional or alternative antimicrobial treatment was
required), or indeterminate (a clinical assessment was not
possible for any reason). The bacteriological response was
evaluated at the 7th day after the discontinuation of anti-
microbial treatment and defined as eradication (no more
positive cultures yielded), presumed eradication (absence of
evaluable culture in a patientwith clinical cure), persistence
(presence of baseline pathogen in a patient with clinical
failure of treatment), presumed persistence (absence of
evaluable culture in a patient with clinical failure of treat-
ment), or indeterminate (if bacteriological response was not
evaluable for any reason). Bacteriological success was
defined if eradicationor presumederadicationwerepresent.
Bacteriological failure was defined as persistence or pre-
sumed persistence.27 The 30 day mortality rates after MRSA
infection were analyzed.
Check the sampling bias of clinical data
To evaluate the sampling bias due to the relatively small
number of patients, a comparison of the clinical data in this
study with the previous report by Pan et al8 was performed
by the c2 test.
Statistical analysis
Comparisons of the categorical data of each study group
were carried out using the c2 test or the Fisher’s exact test,
while comparisons of continuous data were performed
using one-way analysis of variation or the Student t test.
Variables are considered as significantly different if a two-
tailed p < 0.05. Univariate analysis was first conducted to
identify the risk factors associated with mortality. Multi-
variate analysis was then used for the analysis of variables
with a p < 0.05. Isolates were classified into two groups,
i.e., those with vancomycin MIC  1 mg/mL and those with
vancomycin MIC  2 mg/mL. MIC trends were assessed using
nonparametric methods. All analyses were performed using
IBM SPSS Statistics for Windows, version 22.0.0.0 (IBM
Corp., Armonk, NY, USA).Please cite this article in press as: Chen C-P, et al., The association
patients with methicillin-resistant Staphylococcus aureus infections, J
dx.doi.org/10.1016/j.jmii.2015.08.015Results
There were no significant differences in the underlying
diseases between this study and the report by Pan et al8
(p > 0.05). These underlying diseases included diabetes
mellitus, renal insufficiency, cardiovascular diseases,
gastrointestinal diseases, malignancies, neutropenia, res-
piratory diseases, hepatobiliary diseases, autoimmune dis-
eases, previous hospitalization, and previous antibiotic use
(Table 1). There were no significant differences in the
percentages of sources of infection, except for the per-
centage of osteomyelitis being higher in this study than
those reported by Pan et al8 (31.2% vs. 0%, p < 0.001).
There were no significant differences in the 30 day all-
cause mortality and MRSA related 30 day mortality (6.2%
vs. 12.7%, p Z 0.382; 6.2% vs. 4.2%, p Z 0.64,
respectively).
Among the genotypes of 32 isolates, there were 17
(53.1%) isolates with ST239-SCCmecIII, seven (21.9%) iso-
lates with ST5-SCCmecII, six (18.8%) isolates with ST59-
SCCmecIV, and two (6.2%) isolates with ST59-SCCmecVT
(Table 2). The isolates of ST5-SCCmecII and ST239-
SCCmecIII were all health care-associated. For ST59-
SCCmecIV, two isolates were health care-associated and
four isolates were community-associated. Two isolates of
ST59-SCCmecVT were community-associated. The PVL gene
was found in one isolate of ST59-SCCmecIV and two isolates
of ST59-SCCmecVT.of molecular typing, vancomycin MIC, and clinical outcome for
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Table 2 Comparison of molecular characteristics and
clinical outcomes among different sequence types.
Characteristic n (%)
ST5 ST239 ST59 ST59
(n Z 7) (n Z 17) (n Z 6) (n Z 2)
SCCmec II III IV VT
Origin
Health
care-associated
7 (100) 17 (100) 2 (33) 0
Community-acquired 0 0 4 (67) 2 (100)
PVL genes 0 0 1 (17) 2 (100)
Susceptibility
Ciprofloxacin 0 0 6 (100) 2 (100)
Clindamycin 0 2 (12) 1 (17) 0
Rifampicin 0 15 (88) 5 (83) 2 (100)
TMP/SMX 7 (100) 1 (5.8) 6 (100) 2 (100)
Vancomycin 7 (100) 17 (100) 6 (100) 2 (100)
30 d mortality 0 2 (12) 0 0
Diagnosis
Primary BSI 0 4 (24) 0 0
Osteomyelitis 3 (43) 4 (24) 3 (50) 0
Pneumonia 2 (29) 2 (12) 0 0
SSTI 1 (14) 5 (29) 3 (50) 1 (50)
Others 1 (14) 2 (12) 0 1 (50)
BSI Z blood stream infection; PVLZ Panton-Valentine leuko-
cidin; SCCmec Z staphylococcal chromosomal cassette mec;
SSTI Z skin and soft-tissue infection; TMP/
SMX Z trimethoprim/sulfamethoxazole.
4 C.-P. Chen et al.
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SCCmecIV and ST59-SCCmecVT (Table 2). Rifampicin was
active against 88% of 17 isolates with ST239-SCCmecIII and
83% of six isolates with ST59-SCCmecIV. TMP/SMX was
active against all the isolates of ST5-SCCmecII and ST59, but
only active against 5.8% of 17 isolates with ST239-
SCCmecIII. Vancomycin was active against all the 32 iso-
lates. Among the 17 patients with ST239 MRSA infections,
skin and soft tissue infection (29%), bacteremia (24%), and
osteomyelitis (24%) were the most common diseases.
Among the 32 isolates, 11 (34%) isolates had an MIC of
0.5 mg/mL, 19 (60%) isolates had an MIC of 1 mg/mL, and
two (6%) isolates had an MIC of 2 mg/mL (Table 3). Only two
(6%) of 32 isolates had an MIC of 2 mg/mL, and were iden-
tified as ST239-SCCmecIII. The 32 isolates were classified
into two groups by two time periods, i.e., 2003e2005 and
2006e2008 (Table 3). The geometric means of MICs of iso-
lates in the periods of 2003e2008 and 2014 were 0.82 mg/
mL and 0.90 mg/mL, respectively. There was no significant
difference in the percentages of isolates with a vancomycin
MIC  2 mg/mL between the periods of 2003e2008 and 2014
(p > 0.99). No statistically significant change in the distri-
bution of MICs of all isolates was observed during the period
from 2003 to 2014 (pZ 0.263). There was also no significant
difference in the percentages of ST239 isolates with a
vancomycin MIC  2 mg/mL between the periods of
2003e2005 and 2006e2008 (p Z 0.471). Therefore, there
was no vancomycin MIC creep from the periods of 2003 to
2014 in this study.Please cite this article in press as: Chen C-P, et al., The association
patients with methicillin-resistant Staphylococcus aureus infections, J
dx.doi.org/10.1016/j.jmii.2015.08.015Treatment with vancomycin achieved clinical cure and
bacteriological eradication in 30 (94%) of 32 patients.
Central line catheter was a risk factor for 30 day mortality,
according to univariate analysis (Table 4).Discussion
The 30 day all-cause and MRSA-related mortality rate was
6.2% in this study. The mortality rate associated with
invasive MRSA infection varies from 10% to 34%28e30 in
previous studies in different settings. Although two patients
expired with the conditions of septic shock, mechanic
ventilation, and stay in ICU, the number of deaths was too
small to demonstrate these three risk factors as statistically
significant. Septic shock was found to be the only inde-
pendent factor associated with MRSA bacteremia in a
study.31 Score systems for severity of illness and organ
dysfunction have been validated and applied as useful tools
to predict the risk factors of death in patients admitted to
the intensive care unit (ICU), such as the acute physiology
and chronic health evaluation (APACHE),32,33 and sepsis-
related organ failure assessment (SOFA).34 However, the
previous literature did not provide enough information to
assess the accuracy of the prognostic models in patients
with suspected infection in the emergency department and
hospital ward.35 In a recent study, sepsis severity score was
evaluated by assessing the Surviving Sepsis Campaign
database from 2005 to 2009, and the mortality rates were
higher in patients with mechanical ventilation, hypoten-
sion, and stay in ICU.36 The significance of these three risk
factors could be evaluated by further studies.
Ciprofloxacin was active against CA-MRSA (ST59-
SCCmecIV and ST59-SCCmecVT), and TMP/SMX was also
active against ST59-SCCmecIV and ST59-SCCmecVT, and
health care-associated isolates with ST5-SCCmecII, in this
study. Vancomycin was active against all of the isolates.
These susceptibility data are similar to those of other
studies in Taiwan.7,37 In these studies, ciprofloxacin was
active against isolates of ST59 (> 85%). TMP/SMX was active
against isolates with ST5-SCCmecII (> 85%), ST59-SCCmecIV
(> 95%), and ST59-SCCmecVT (> 95%).
7,37
Only two isolates with the genotype of ST239-SCCmecIII
were revealed to have a high vancomycin MIC of 2 mg/mL in
this study. The high vancomycin MIC of 2 mg/mL in MRSA
isolates is attributable to the spread of the predominant
ST239 strain.38,39 The susceptibility tests for 470 MRSA
isolates were performed by agar dilution in a hospital in
northern Taiwan.40 Among the 250 MRSA isolates of ST239,
there were 29% of isolates with a vancomycin MIC of 2 mg/
mL, 70% of isolates with a vancomycin MIC of 1 mg/mL, and
1% of isolates with a vancomycin MIC of 0.5 mg/mL (Table
3).40 MRSA of ST239 is multiply antibiotic-resistant and ac-
counts for the most predominant strain of HA-MRSA
throughout Asia, South America, and Eastern Europe.41e47
Seven (22%) isolates were identified as ST5-SCCmecII in
this study, although a high vancomycin MIC  2 mg/mL
against this clone was not detected. However, six (8%) of 74
isolates with ST5 have a vancomycin MIC of 2 mg/mL in that
Taiwanese hospital.40 ST5 was first identified as a nosoco-
mial clone in 2000 in another Taiwanese hospital and
became the major clone colonizing adult patients in ICUs inof molecular typing, vancomycin MIC, and clinical outcome for
ournal of Microbiology, Immunology and Infection (2015), http://
Table 3 Trends of vancomycin minimum inhibitory concentrations (MICs) among different sequence types of methicillin-
resistant Staphylococcus aureus (MRSA).
No. Range of vancomycin MICs, n (%) p
Phoenix automated microbiology system
0.5 mg/mL 1 mg/mL 2 mg/mL GM (mg/mL)
2003e2005
ST5 6 3 (50) 3 (50) 0 0.70
ST59 3 0 3 (100) 0 1
ST239 9 1 (11) 6 (67) 2 (22) 1.08
2006e2008
ST5 1 1 (100) 0 0 0.5
ST59 5 4 (80) 1 (20) 0 0.57
ST239 8 2 (25) 6 (75) 0 0.84 0.471a
Total (2003
e2008)
32 11 (34) 19 (60) 2 (6) 0.82
2014 28 5 (18) 22 (79) 1 (3) 0.90 > 0.99b 0.263c
Kao et al40 Agar dilution method
2006e2008 0.5 mg/mL 1 mg/mL 2 mg/mL
ST5 74 3 (4.1) 65 (87.8) 6 (8.1)
ST59 109 19 (17.4) 90 (82.6) 0
ST239 250 2 (0.8) 175 (70) 73 (29.2)
Yeh et al31 E test
< 1.5 mg/mL  1.5 mg/mL GM (mg/mL)
2001 45 26 (57.8) 19 (42.2) 1.19
2005 46 38 (82.6) 8 (17.4) 0.99
2009 49 14 (28.6) 35 (71.4) 1.39
GM Z geometric mean.
a c2 test, indicates the probability of significant difference in the percentages of ST239 isolates with a vancomycin MIC  2 mg/mL
between the periods of 2003e2005 and 2006e2008.
b c2 test, indicates the probability of significant difference in the percentages of isolates with a vancomycin MIC  2 mg/mL between
the periods of 2003e2008 and 2014.
c ManneWhitney U test, indicates the probability of significant change in the distribution of MICs of all isolates between the periods of
2003e2014 (p Z 0.263).
Vancomycin MIC and clinical outcome of MRSA 5
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sequence types and antimicrobial susceptibility of MRSA is
needed to evaluate the impact of development of MRSA
clones with high vancomycin MIC on the clinical outcome.
The phenomenon, vancomycin MIC creep, was not pre-
sent and MRSA with a high vancomycin MIC of 2 mg/mL didTable 4 Factors independently associated with mortality
for patients with methicillin-resistant Staphylococcus
aureus (MRSA) infection.
Factor OR (95% CI) p
Diabetes mellitus 5.0 (0.266e93.958) 0.345
Gastrointestinal diseases 9.0 (0.440e183.973) 0.238
Malignancies 9.0 (0.440e183.973) 0.238
Central line catheter 1.667 (0.815e3.409) 0.020
Shock 1.333 (0.894e1.989) 0.056
Mechanical ventilation 1.286 (0.907e1.823) 0.073
ICU stay 1.25 (0.917e1.704) 0.091
CIZ confidence interval; ICUZ intensive care unit; ORZ odds
ratio.
Please cite this article in press as: Chen C-P, et al., The association
patients with methicillin-resistant Staphylococcus aureus infections, J
dx.doi.org/10.1016/j.jmii.2015.08.015not result in a higher mortality rate in this study. Vanco-
mycin MIC creep has been reported in some studies.11,12,51
An increase of vancomycin MIC in a northern Taiwanese
hospital was also reported.31 According to the report, 42%
of 45 MRSA isolates had a vancomycin MIC  1.5 mg/mL in
2001, and 71.4% of 49 MRSA isolates had a vancomycin MIC
 1.5 mg/mL in 2009 (Table 3). However, there was no
significant difference in the in-hospital mortality rates be-
tween patients with MRSA isolates with MICs < 1.5 mg/mL or
 1.5 mg/mL.31 By contrast, there were several discordant
reports for vancomycin MIC creep.52,53 Reports from large
multicenter surveillance studies have not reported changes
in vancomycin susceptibilities over time54,55 Combining
data from multiple centers can obscure the MIC trends that
may exist within a given institution or a geographic region
as a result of differences in patient populations and anti-
microbial usage patterns.12,53 The use of less sensitive
traditional susceptibility parameters (e.g., percentages,
MIC50, and MIC90) in their analyses will limit the ability to
detect MIC creep and their magnitude in MIC pop-
ulations.12,52 Vancomycin MICs produced by Etest have a
tendency to be 0.5e1.5 log2 dilutions higher than those byof molecular typing, vancomycin MIC, and clinical outcome for
ournal of Microbiology, Immunology and Infection (2015), http://
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ranted to determine if such small differences in the van-
comycin MIC are indeed significant, and therapeutic
recommendations should specify the MIC method on which
they are based.57
There were some limitations in this study. First, the
number of isolates is small. However, there were some
major MRSA clones spreading in Taiwan, and each clone has
its microbiological characteristics. It is expected that these
isolates could have the microbiological characteristics of
the major clones, although this is not a large scale study.
Second, the number of deaths was not large enough to
demonstrate statistical significance in the risk factors of
mortality, although the odds ratios were high. Third, the
MICs determined by the Phoenix automated microbiology
system could have a tendency to be lower than those per-
formed by the Etest. The clinical significance of these small
differences in the vancomycin MIC should be clarified by
further studies.
In conclusion, there was no vancomycin MIC creep from
the periods of 2003 to 2014 in this study. There was no
significant difference in the mortality rates between two
groups of patients with vancomycin MICs < 2 mg/mL and 
2 mg/mL (p > 0.99). Appropriate prognostic models for
assessment of the association among sequence types, van-
comycin MICs, and clinical outcome warrant further
investigation.
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